| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/20/2023 | 0.74% | Goldman Sachs | → $19 | Initiates Coverage On | → Neutral |
| 11/10/2023 | 165.11% | HC Wainwright & Co. | $42 → $50 | Maintains | Buy |
| 09/11/2023 | 159.81% | Guggenheim | $46 → $49 | Maintains | Buy |
| 08/14/2023 | 143.9% | Guggenheim | → $46 | Reiterates | Buy → Buy |
| 08/11/2023 | 122.69% | HC Wainwright & Co. | $50 → $42 | Maintains | Buy |
| 07/26/2023 | 165.11% | HC Wainwright & Co. | $44 → $50 | Maintains | Buy |
| 07/18/2023 | 133.3% | William Blair | → $44 | Initiates Coverage On | → Outperform |
| 06/26/2023 | 133.3% | HC Wainwright & Co. | $40 → $44 | Maintains | Buy |
| 06/16/2023 | 122.69% | Guggenheim | $40 → $42 | Maintains | Buy |
| 05/18/2023 | — | Guggenheim | Initiates Coverage On | → Buy | |
| 05/08/2023 | 128% | Oppenheimer | → $43 | Reiterates | → Outperform |
| 03/15/2023 | 112.09% | HC Wainwright & Co. | → $40 | Reiterates | → Buy |
| 08/01/2022 | 112.09% | Barclays | → $40 | Initiates Coverage On | → Overweight |
| 12/21/2021 | 112.09% | HC Wainwright & Co. | → $40 | Initiates Coverage On | → Buy |
| 11/23/2021 | 191.62% | Oppenheimer | → $55 | Initiates Coverage On | → Outperform |
| 10/08/2021 | 244.64% | Raymond James | $50 → $65 | Maintains | Strong Buy |
| 06/29/2021 | 165.11% | Raymond James | $39 → $50 | Maintains | Strong Buy |
| 11/10/2020 | 122.69% | Ladenburg Thalmann | → $42 | Initiates Coverage On | → Buy |
| 11/10/2020 | 74.97% | B of A Securities | → $33 | Initiates Coverage On | → Buy |
| 11/10/2020 | 85.58% | Jefferies | → $35 | Initiates Coverage On | → Buy |
| 11/10/2020 | 106.79% | Raymond James | → $39 | Initiates Coverage On | → Strong Buy |
What is the target price for Tarsus Pharmaceuticals (TARS)?
The latest price target for Tarsus Pharmaceuticals (NASDAQ: TARS) was reported by Goldman Sachs on November 20, 2023. The analyst firm set a price target for $19.00 expecting TARS to rise to within 12 months (a possible 0.74% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Tarsus Pharmaceuticals (TARS)?
The latest analyst rating for Tarsus Pharmaceuticals (NASDAQ: TARS) was provided by Goldman Sachs, and Tarsus Pharmaceuticals initiated their neutral rating.
When is the next analyst rating going to be posted or updated for Tarsus Pharmaceuticals (TARS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tarsus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tarsus Pharmaceuticals was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
Is the Analyst Rating Tarsus Pharmaceuticals (TARS) correct?
While ratings are subjective and will change, the latest Tarsus Pharmaceuticals (TARS) rating was a initiated with a price target of $0.00 to $19.00. The current price Tarsus Pharmaceuticals (TARS) is trading at is $18.86, which is within the analyst's predicted range.